Navigation Links
CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
Date:5/10/2010

SEOUL, South Korea, May 10 /PRNewswire/ -- CrystalGenomics, Inc., a novel drug R&D company announced today that the Phase I SAD (Single Ascending Dose) study for its novel antibiotic candidate, CG400549, has been successfully completed in Europe.

CG400549 is a potential first-in-class antibiotic candidate targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme in generating bacterial membrane) as it has novel chemical structure which has never been used as an antibacterial agent previously. CG400549 is being developed to target the notorious resistant bacterial strains including MRSA (Methicillin Resistant Staphylococcus aureus) and VRSA (Vancomycin Resistant Staphylococcus aureus), or commonly referred to as the "super bug." CG400549 has successfully completed the Phase I SAD study in Europe and has just received an approval for its Phase I MAD (Multiple Ascending Dose) study from the Ethics Committee.

The objective of the SAD study was to evaluate safety, tolerability and pharmacokinetic characteristics of CG400549 in healthy volunteers. The study demonstrated that CG400549 was safe and well tolerated among all subjects.  

Now that the Ethics Committee has granted an approval for the MAD study, CrystalGenomics plans to initiate the study which will further examine the safety and tolerability profiles of CG400549.

Joong Myung Cho, Ph.D., President & CEO of CrystalGenomics said: "We are very pleased with the SAD study results and this enables us to begin the next Phase I study with a high level of confidence. We anticipate completing the MAD study and will make our transition into Phase IIa clinical trial by the end of this year."

About CrystalGenomics

CrystalGenomics, Inc. is a publicly-held company dedicated to the discovery and development of novel drug candidates in the areas of cancer, CNS, inflammation, and infectious diseases. The lead candidate, CG100649 is a next generation NSAID which has completed a Phase IIa trial in Europe and CG200745 for molecular target cancer therapeutics is Phase I ready. The company has competitive and proprietary platform technologies for structural biology, structure-based novel scaffold/lead design, lead optimization and candidate selection. CrystalGenomics is headquartered in Seoul, Korea and its subsidiary, CG Pharmaceuticals Inc., is located in Emeryville, California for US and EU clinical management. For more information on CrystalGenomics, please visit: www.cgxinc.com

CONTACT: Steven Kim, +82-2-3010-8611, skim@cgxinc.com


'/>"/>
SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals Announces Public Offering of Common Stock
2. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
3. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
4. CareFusion Announces Agreement With Banner Health to Upgrade and Extend Pyxis Medication Solutions
5. Xanodyne Announces Renewed Focus on Pain Management Market
6. Medco Announces Webcast for Annual Meeting of Shareholders
7. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer
8. Hill-Rom Announces Third Quarter 2010 Dividend
9. Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2010 Results
10. ADVENTRX Pharmaceuticals Announces Closing of Financing
11. China Pharma Holdings, Inc. Announces May Investor Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... Ste phen Schmidt Join the ... software solutions for life sciences, today announced key new leaders have ... insight to a growing business.  This will bolster the company,s safety ... joined ArisGlobal in the position of Vice President - Safety. ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... ... Each year, about 800,000 people suffer from cerebral vascular accidents, or strokes. ... for one death every four minutes. Many people who survive a stroke are ... a video series called “Your Brain,” in conjunction with its medical journal “Balance,” in ...
(Date:5/3/2016)... Toronto, ON (PRWEB) , ... May 03, 2016 ... ... been recognized as one of Canada’s top Information and Communication Technology (ICT) companies ... top Canadian and Multinational ICT companies operating in Canada, as ranked by revenue. ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Branches, Inc. ... its Grow & Climb children and youth programs in South Miami. Macy’s is a ... , The Grow Program provides afterschool tutoring, mentoring, enrichment and academic support to ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... healthcare organizations, especially medium and small physician practices, to better grasp and implement ... step-by-step approach that guides practices on a well-defined, expert-created path to compliance. HIPAA ...
(Date:5/2/2016)... Denver, CO (PRWEB) , ... May 02, 2016 , ... ... will serve as the keynote speaker for five events throughout the month of May. ... for a number of national news outlets. He also frequently appears on the Science ...
Breaking Medicine News(10 mins):